Competitive neuromuscular

Neostigmine preceded by atropine to block muscarinic effects rapidly reverses muscle paralysis induced by competitive neuromuscular blockers (decurarization). 

Mechanism of action of competitive neuromuscular blocking drugs. 

Myasthenia gravis is made worse by quinine and quinidine and myasthenics are intolerant of competitive neuromuscular blocking agents and aminoglycoside antibiotics. 

Hughes R, Chappie DJ. The pharmacology of atracurium a new competitive neuromuscular blocking agent. Br J Anaesth 1981 53(1) 31 4. 

Clancy M, Halford S, Walls R, Murphy M. In patients with head injuries who undergo rapid sequence intubation using succinylcholine, does pretreatment with a competitive neuromuscular blocking agent improve outcome A hterature review. Emerg Med J 2001 18(5) 373-5. 

Faverin fluvoxamine. fazadinium bromide [ban. inn] is a bisquaternary amine complex heterocyclic compound, which acts as a NICOTINIC cholinoceptor ANTAGONIST, a (competitive) NEUROMUSCULAR BLOCKING AGENT. It can be used as a SKELETAL MUSCLE RELAXANT in anaesthesia, fazarabine [inn, usan] (Ara-Ac NSC 281272) is an analogue of cytarabine, an antimetabolite cytotoxic agent that has been used in ANTICANCER treatment. 

Ro 1-5130 Mestinon Regonol ) is a quaternary ammonium compound that is a reversible ANTICHOLINESTERASE. It can be used by injection at the termination of operations to reverse the actions of (competitive) NEUROMUSCULAR BLOCKING AGENTS (when it iS often administered with atropine), and as a diagnostic agent for myasthenia gravis. It can also be used as a... 

Bolger, L., Brittain, R. T., Jack, D., Jackson, M. R., Martin, L. E., Mills, J., Poynter, D., Tyers, M. B. Short-lasting, competitive neuromuscular blocking activity in a series of azobis-arylimidazo-[l,2-Oi]-pyridinium dihalides. Nature 238, 354 (1972). 

Current use of anti-AChE agents is limited to four conditions in the periphery atony of the smooth muscle of the intestinal tract and urinary bladder, glaucoma, myasthenia gravis, and reversal of the paralysis of competitive neuromuscular blocking drags. Long-acting and hydrophobic... 

Metocurine, a skeletal muscle relaxant, is indicated as an adjunct to anesthesia, to facilitate endotracheal intubation (0.2 to 0.4 mg/kg), and to reduce the intensity of muscle contraction in pharmacologically or electrically induced convulsions. Metocurine is a methyl analog of tubocurarine, which produces nondepolarizing (competitive) neuromuscular blockade. 

Edrophonium is very short-acting, so is not used for treatment. Its major uses are in diagnostic procedures, such as the diagnosis of myasthenia gravis. It is also used to reverse the effects of competitive neuromuscular blockade (e.g., d-tubocurarine) after surgery. 

These are also known as the competitive neuromuscular blocking drugs. In a situation, when the impulses in the somatic nerve arrive at the specific region located in the nerve terminals in the motor end-plate, they eventually elicit the release of acetylcholine (ACh), which in turn gets diffused to the post-synaptic motor end-plate membrane. Thus, ACH combines with nicotinic cholinergic receptors to activate them that ultimately leads to the opening of transmembrane ion channels, ion-flow, and as a result affords membrane depolarization. Importantly, end-plate membrane depolarization is usually accompanied by depolarization of the muscle membrane and ultimately leads to muscle contraction In short, any plausible and feasible interruption of the aforesaid squence of events gives rise to the muscular paralysis. 

C. This drug may potentiate competitive neuromuscular blockers (see p 472). 

---